- Home
- BMRN vs TOL Comparison
BMRN vs TOL Comparison
Compare BMRN & TOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- TOL
- Stock Information
- Founded
- BMRN 1996
- TOL 1967
- Country
- BMRN United States
- TOL United States
- Employees
- BMRN N/A
- TOL N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- TOL Homebuilding
- Sector
- BMRN Health Care
- TOL Consumer Discretionary
- Exchange
- BMRN Nasdaq
- TOL Nasdaq
- Market Cap
- BMRN 16.1B
- TOL 13.1B
- IPO Year
- BMRN 1999
- TOL N/A
- Fundamental
- Price
- BMRN $69.47
- TOL $156.76
- Analyst Decision
- BMRN Buy
- TOL Buy
- Analyst Count
- BMRN 19
- TOL 16
- Target Price
- BMRN $97.37
- TOL $146.25
- AVG Volume (30 Days)
- BMRN 1.4M
- TOL 1.2M
- Earning Date
- BMRN 10-29-2024
- TOL 12-03-2024
- Dividend Yield
- BMRN N/A
- TOL 0.59%
- EPS Growth
- BMRN 154.24
- TOL 4.19
- EPS
- BMRN 1.33
- TOL 14.53
- Revenue
- BMRN $2,588,398,000.00
- TOL $10,533,425,000.00
- Revenue This Year
- BMRN $17.93
- TOL $6.80
- Revenue Next Year
- BMRN $11.11
- TOL $3.64
- P/E Ratio
- BMRN $52.13
- TOL $10.79
- Revenue Growth
- BMRN 15.83
- TOL N/A
- 52 Week Low
- BMRN $67.75
- TOL $68.08
- 52 Week High
- BMRN $99.56
- TOL $158.93
- Technical
- Relative Strength Index (RSI)
- BMRN 34.18
- TOL 63.54
- Support Level
- BMRN $69.53
- TOL $147.90
- Resistance Level
- BMRN $70.90
- TOL $158.93
- Average True Range (ATR)
- BMRN 1.18
- TOL 3.25
- MACD
- BMRN 0.70
- TOL -0.01
- Stochastic Oscillator
- BMRN 49.14
- TOL 81.69
About BMRN BioMarin Pharmaceutical Inc.
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-home buyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the U.S. It has its headquarters in Horsham, Pennsylvania.